115 related articles for article (PubMed ID: 9592252)
21. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
[TBL] [Abstract][Full Text] [Related]
22. Enhancement of lymphokine-activated killer cell induction using anti-CD25 and anti-CTLA-4 monoclonal antibodies.
Okita R; Yamaguchi Y; Emi A; Matsuura K; Toge T
Oncol Rep; 2007 Jun; 17(6):1429-35. PubMed ID: 17487401
[TBL] [Abstract][Full Text] [Related]
23. Induction of bone formation in an adenoid cystic carcinoma of the maxillary sinus by adoptive immunotherapy involving intra-arterial injection of lymphokine-activated killer cells and recombinant interleukin-2 in combination with radiotherapy.
Sato M; Yoshida H; Kaji R; Okamoto M; Iga H; Kawamata H; Kobayashi S; Aladib W; Yanagawa T; Takegawa Y
J Biol Response Mod; 1990 Jun; 9(3):329-34. PubMed ID: 2166140
[TBL] [Abstract][Full Text] [Related]
24. [Preparation of NK-enriched LAK cells--their potential cytotoxic and ADCC activities].
Kobayashi Y; Sudo T; Matsushita N; Nakao M; Tanaka Y; Shimizu K; Tanigawa K; Aruga A
Gan To Kagaku Ryoho; 2003 Oct; 30(11):1776-9. PubMed ID: 14619517
[TBL] [Abstract][Full Text] [Related]
25. Cancer cell cycle and adoptive immunotherapy using lymphokine-activated killer cells.
Ejiri Y; Ohara M; Suzuki T; Kasukawa R
Fukushima J Med Sci; 1997 Dec; 43(2):61-73. PubMed ID: 9640842
[TBL] [Abstract][Full Text] [Related]
26. Adenoid cystic carcinoma of the minor salivary glands: long-term survival with planned combined therapy.
Rice DH
Arch Otolaryngol; 1981 Feb; 107(2):128. PubMed ID: 6258546
[No Abstract] [Full Text] [Related]
27. [Cystic adenoid carcinoma of the salivary glands].
Verhulst J; Païva A
Rev Laryngol Otol Rhinol (Bord); 1982; 103(2):97-9. PubMed ID: 6293030
[No Abstract] [Full Text] [Related]
28. Loss of CYLD might be associated with development of salivary gland tumors.
Fukuda M; Hiroi M; Suzuki S; Ohmori Y; Sakashita H
Oncol Rep; 2008 Jun; 19(6):1421-7. PubMed ID: 18497946
[TBL] [Abstract][Full Text] [Related]
29. Combined antitumour activity of mitomycin C, 5-fluorouracil and interleukin-2 against human colon cancer cells.
Ishihara M; Kubota T; Watanabe M; Kawano Y; Narai S; Yasui N; Otani Y; Teramoto T; Kitajima M
Anticancer Res; 1999; 19(1A):313-6. PubMed ID: 10226560
[TBL] [Abstract][Full Text] [Related]
30. Adenoid cystic carcinoma of salivary and lacrimal gland origin: localization, classification, clinical pathological correlation, treatment results and long-term follow-up control in 84 patients.
Friedrich RE; Bleckmann V
Anticancer Res; 2003; 23(2A):931-40. PubMed ID: 12820326
[TBL] [Abstract][Full Text] [Related]
31. Assessment of p63 expression in the salivary gland neoplasms adenoid cystic carcinoma, polymorphous low-grade adenocarcinoma, and basal cell and canalicular adenomas.
Edwards PC; Bhuiya T; Kelsch RD
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2004 May; 97(5):613-9. PubMed ID: 15153875
[TBL] [Abstract][Full Text] [Related]
32. Combinational IL-2/IL-15 induction does not further enhance IL-15-induced lymphokine-activated killer cell cytotoxicity against human leukemia/lymphoma cells.
Ozdemir O; Savaşan S
Clin Immunol; 2005 Jun; 115(3):240-9. PubMed ID: 15893691
[TBL] [Abstract][Full Text] [Related]
33. [The selection of highly lung metastatic salivary adenoid cystic carcinoma clone].
Guan X; Qiu W; He R
Zhonghua Kou Qiang Yi Xue Za Zhi; 1996 Mar; 31(2):74-7. PubMed ID: 9387535
[TBL] [Abstract][Full Text] [Related]
34. B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome.
Ittah M; Miceli-Richard C; Eric Gottenberg J; Lavie F; Lazure T; Ba N; Sellam J; Lepajolec C; Mariette X
Arthritis Res Ther; 2006; 8(2):R51. PubMed ID: 16507175
[TBL] [Abstract][Full Text] [Related]
35. A combined lymphokine-activated killer (LAK) cell immunotherapy and adenovirus-p53 gene therapy for head and neck squamous cell carcinoma.
Saito H; Ando S; Morishita N; Lee KM; Dator D; Dy D; Shigemura K; Adhim Z; Nibu K; Fujisawa M; Shirakawa T
Anticancer Res; 2014 Jul; 34(7):3365-70. PubMed ID: 24982341
[TBL] [Abstract][Full Text] [Related]
36. Locoregional immunochemotherapy in hepatocellular carcinoma.
Kountouras J; Boura P; Kouklakis G
Hepatogastroenterology; 2002; 49(46):1109-12. PubMed ID: 12143214
[TBL] [Abstract][Full Text] [Related]
37. [The effects of suicide gene therapy system on adenoid cystic carcinoma of salivary gland in athymic mice].
Sun C; He R; Zhang Z
Zhonghua Kou Qiang Yi Xue Za Zhi; 2000 Jan; 35(1):34-7. PubMed ID: 11831960
[TBL] [Abstract][Full Text] [Related]
38. Cooperation between CD44 and LFA-1/CD11a adhesion receptors in lymphokine-activated killer cell cytotoxicity.
Matsumoto G; Nghiem MP; Nozaki N; Schmits R; Penninger JM
J Immunol; 1998 Jun; 160(12):5781-9. PubMed ID: 9637488
[TBL] [Abstract][Full Text] [Related]
39. Interferon gamma but not tumor necrosis factor alpha decreases susceptibility of human renal cell cancer cell lines to lymphokine-activated killer cells.
Tomita Y; Watanabe H; Kobayashi H; Nishiyama T; Tsuji S; Fujiwara M; Sato S
Cancer Immunol Immunother; 1992; 35(6):381-7. PubMed ID: 1356627
[TBL] [Abstract][Full Text] [Related]
40. Lymphokine-activated killer cells can kill target cells not only by early killing but also by late killing, and the late killing level against autotumor cell line.
Komatsu F; Ishiguro K
Oncol Res; 2003; 13(4):235-41. PubMed ID: 12659424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
